AllianceRx Walgreens Prime Launches Digital Clinical Tools

As the COVID-19 pandemic wears on, it’s more important than ever for people to have the ability to perform needed actions from home. To help with this, AllianceRx Walgreens Prime has released some digital clinical assessments that allow people with certain illnesses to manage their conditions online and remain adherent to therapy.

The assessments are available for people with chronic inflammatory disease, cystic fibrosis, idiopathic pulmonary fibrosis, lipid and blood disorders, multiple sclerosis and organ transplants. Asked how the company decided upon those conditions, James Adams, chief information officer at AllianceRx Walgreens Prime, says that it “took a strategic approach” that “was based on patient volume, diseases and conditions with lower risk, as well as stability of patients. The chronic inflammatory disease (CID) space was our first program to implement digitally with patients already established on therapy. This included patients with conditions such as rheumatoid arthritis, psoriasis, atopic dermatitis, ulcerative colitis, ankylosing spondylitis and others.”

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Another-Immunotherapy-Indication-Will-Be-Withdrawn.jpg
November 16

FDA Grants Interchangeable Status to Humira Biosimilar; Payers Should Prepare Now for 2023 Launches

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image_NSCLC.jpg
November 16

New Tecartus FDA Approval for Adults With ALL Offers Welcome Therapeutic Option

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Specialty-Trend-Increase-Slows-Biosimilars-Are-Having-Impact.jpg
November 16

Prime Therapeutics Launches IntegratedRx – Oncology, Partners on MIP Accreditation

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today